Update on USFDA inspection at Pashamylaram Manufacturing facility.

7 November 2026 To To The Listing Department, The Department of Corporate Services, National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), P. J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Symbol: COHANCE Code – 543064 Dear Sir/Madam, Sub: Update on USFDA Inspection for Company’s Pashamylaram Manufacturing Facility Further to our earlier communication dated 5 August 2026 regarding the inspection by the United States Food and Drug Administration (USFDA) at the Company's manufacturing facility located at Pashamylaram, Hyderabad (FEI No. 1000623515), we wish to update that USFDA has issued the Establishment Inspection Report (EIR) in respect of the aforesaid facility and has classified the inspection outcome as Voluntary Action Indicated (VAI). With the receipt of the EIR, the said inspection stands concluded. Kindly take the above information on record. Thank you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K Mishra Company Secretary and Compliance Officer